Darrin Crisitello, Chief Commercial Officer, Mission Bio
At Mission Bio, everyone at the company is pushing forward with science that can improve patient care in a meaningful way. Upon recently joining, I immediately noticed that collaboration is a thread of the culture. In addition to building the best teams and hiring top talent, it also means partnering with the right organizations to deliver on our mission: to help researchers and clinicians unlock single-cell biology to enable the discovery, development and delivery of precision medicine.
Identifying precision cancer treatments often involves broad-based next-generation sequencing (NGS). This method provides an average molecular profile of all the cells in the patient’s sample, but often masks genetic diversity and overlooks the rare cells that can drive therapy resistance and disease progression. While there has been much talk about precision medicine over the past decade, unfortunately there has been limited application of matching patients with specific medications. Partially because we have lacked the tools necessary to accurately measure underlying genetic diversity that can better match a specific drug target to diseased cells in a patient.
In order to improve upon both of these areas, Mission Bio has recently announced our partnership with LabCorp, a world-class organization focused on improving the health and lives of patients globally. They offer an unrivaled clinical test menu and CRO services through Covance for pharmaceutical companies throughout their drug development pipeline. This partnership allows them to look to the best of innovative technologies that will have major clinical and patient impact, and we are honored to be partnering with them.
Together, we look to service our pharma customers better with our unique offering to identify meaningful biomarkers only accessible through single-cell DNA analysis. To predict non-responders earlier in a clinical trial with detection of therapy-resistant/therapy-induced mutations; and to define a clearer, genomic-driven endpoint where a clinician can be notified right away on a pending patient relapse, rather than awaiting a symptomatic one. And with our continuing innovation in multi-omics, single-cell DNA analysis is just the beginning of our offerings to help clinicians and patients and I am excited to be apart of the journey.
About Mission Bio
Mission Bio delivers targeted solutions for high impact applications with Tapestri Platform. The Tapestri Platform is the industry’s first single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables and software, which plug seamlessly into existing NGS workflows. The company’s Tapestri Platform was also honored as a Top 10 Innovation of 2018 by The Scientist, as well as utilized by researchers at MD Anderson Cancer Center (MDACC) for the largest single-cell study completed to date. Additional studies in therapy resistance and Minimal Residual Disease (MRD) using the Tapestri Platform have been reported by other leading cancer centers, including the University of California, San Francisco, University of Pennsylvania, and Stanford University. With Mission Bio, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.
Spun out of research at the University of California, San Francisco, Mission Bio is headquartered in South San Francisco, California.
To learn more, please visit missionbio.com.
